Back to Search Start Over

New models towards assessing anti-cancer therapeutics

Authors :
Junta de Castilla y León
Ministerio de Ciencia e Innovación (España)
European Commission
Fundación Sandra Ibarra - Solidaridad Frente al Cáncer
National Institutes of Health (US)
Fundación Eugenio Rodríguez Pascual
Obra Social Kutxa
Romero-Camarero, Isabel
Barajas-Diego, Marcos
Castellanos-Martín, Andrés
García Martín, Ángel
Varela, Gonzalo
Abad, María del Mar
Ludeña, María Dolores
Pérez-Losada, J.
Sánchez García, Isidro
Junta de Castilla y León
Ministerio de Ciencia e Innovación (España)
European Commission
Fundación Sandra Ibarra - Solidaridad Frente al Cáncer
National Institutes of Health (US)
Fundación Eugenio Rodríguez Pascual
Obra Social Kutxa
Romero-Camarero, Isabel
Barajas-Diego, Marcos
Castellanos-Martín, Andrés
García Martín, Ángel
Varela, Gonzalo
Abad, María del Mar
Ludeña, María Dolores
Pérez-Losada, J.
Sánchez García, Isidro
Publication Year :
2012

Abstract

Cancer is the subject of intense research around the world, but many questions about how the disease works remain unanswered. How exactly does cancer start and how do tumours grow? In fact, at present there are ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. However, many of the new anticancer agents are predicted to show clinical benefit in only small subpopulations of patients. The cancer stem cell model could explain not only how some cancers work but also why patients suffer relapses, providing a good opportunity to gain insight into the reasons why agents work or, more commonly, don't work, before going into a clinical trial.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1103393566
Document Type :
Electronic Resource